Naveen Pemmaraju, MD, The University of Texas, MD Anderson Cancer Center, Houston, TX, discusses the development of novel JAK inhibitors beyond ruxolitinib and fedratinib, add-on strategies with pelabresib, and novel monotherapies such as LSD1 inhibition for the treatment of myeloproliferative neoplasms (MPNs). Dr Pemmaraju also discusses dual-oral therapy, another approach which is increasingly gaining attention. This interview took place at the Texas MPN Workshop: Second Annual Workshop and Meeting in 2021.
